[go: up one dir, main page]

WO2006031420A3 - Comprimes multicouche et formes posologiques bioadhesives - Google Patents

Comprimes multicouche et formes posologiques bioadhesives Download PDF

Info

Publication number
WO2006031420A3
WO2006031420A3 PCT/US2005/030651 US2005030651W WO2006031420A3 WO 2006031420 A3 WO2006031420 A3 WO 2006031420A3 US 2005030651 W US2005030651 W US 2005030651W WO 2006031420 A3 WO2006031420 A3 WO 2006031420A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
layer tablets
dosage form
retention time
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/030651
Other languages
English (en)
Other versions
WO2006031420A2 (fr
Inventor
Avinash Nangia
Jules Jacob
Edith Mathiowitz
Thomas L Ricketts
Mark R Kreitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spherics Inc
Original Assignee
Spherics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/009,327 external-priority patent/US20050201974A1/en
Priority claimed from PCT/US2005/007525 external-priority patent/WO2005084639A2/fr
Application filed by Spherics Inc filed Critical Spherics Inc
Priority to EP05792519A priority Critical patent/EP1784167A2/fr
Priority to CA002578845A priority patent/CA2578845A1/fr
Priority to US11/661,541 priority patent/US20080311191A1/en
Priority to AU2005285298A priority patent/AU2005285298A1/en
Priority to JP2007530225A priority patent/JP2008516893A/ja
Publication of WO2006031420A2 publication Critical patent/WO2006031420A2/fr
Publication of WO2006031420A3 publication Critical patent/WO2006031420A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des enrobages bioadhésifs qui augmentent le temps de séjour gastro-intestinal de médicaments ingérés par voie orale. Certains enrobages bioadhésifs possèdent une résistance à la rupture d'au moins 100 N/m2, mesurée sur un intestin de rat, lorsqu'ils sont appliqués sur une surface d'une forme posologique pharmaceutique destinée à l'administration d'un médicament par voie orale. Cette caractéristique permet d'obtenir un temps de séjour gastro-intestinal d'au moins 4 jours chez un chien de race beagle qui est alimenté, période durant laquelle le médicament est libéré par la forme posologique. L'invention concerne également des comprimés multicouche, en particulier ceux contenant des excipients hydrophobes, pouvant être utilisés pour administrer des médicaments hygroscopes et/ou déliquescents. Par ailleurs, en variant la concentration de médicament dans les comprimés multicouche, on régule la vitesse de libération du médicament.
PCT/US2005/030651 2004-08-27 2005-08-29 Comprimes multicouche et formes posologiques bioadhesives Ceased WO2006031420A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05792519A EP1784167A2 (fr) 2004-08-27 2005-08-29 Comprimes multicouche et formes posologiques bioadhesives
CA002578845A CA2578845A1 (fr) 2004-08-27 2005-08-29 Comprimes multicouche et formes posologiques bioadhesives
US11/661,541 US20080311191A1 (en) 2004-08-27 2005-08-29 Multi-Layer Tablets and Bioadhesive Dosage Forms
AU2005285298A AU2005285298A1 (en) 2004-08-27 2005-08-29 Multi-layer tablets and bioadhesive dosage forms
JP2007530225A JP2008516893A (ja) 2004-08-27 2005-08-29 多層錠剤および生体接着性剤形

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US60519904P 2004-08-27 2004-08-27
US60499004P 2004-08-27 2004-08-27
US60520004P 2004-08-27 2004-08-27
US60499104P 2004-08-27 2004-08-27
US60519804P 2004-08-27 2004-08-27
US60520104P 2004-08-27 2004-08-27
US60/605198 2004-08-27
US60/605200 2004-08-27
US60/604990 2004-08-27
US60/605201 2004-08-27
US60/604991 2004-08-27
US60/605199 2004-08-27
US60790504P 2004-09-08 2004-09-08
US60/607905 2004-09-08
US11/009,327 2004-12-09
US11/009,327 US20050201974A1 (en) 2003-12-09 2004-12-09 Bioadhesive polymers with catechol functionality
US63581204P 2004-12-13 2004-12-13
US60/635812 2004-12-13
US65037505P 2005-02-04 2005-02-04
US65019105P 2005-02-04 2005-02-04
US60/650375 2005-02-04
US60/650191 2005-02-04
PCT/US2005/007525 WO2005084639A2 (fr) 2004-03-03 2005-03-03 Systeme d'administration de medicaments polymeres pour des medicaments hydrophobes
USPCT/US2005/007525 2005-03-03
US67638305P 2005-04-29 2005-04-29
US60/676383 2005-04-29

Publications (2)

Publication Number Publication Date
WO2006031420A2 WO2006031420A2 (fr) 2006-03-23
WO2006031420A3 true WO2006031420A3 (fr) 2006-11-30

Family

ID=35703299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030651 Ceased WO2006031420A2 (fr) 2004-08-27 2005-08-29 Comprimes multicouche et formes posologiques bioadhesives

Country Status (4)

Country Link
EP (1) EP1784167A2 (fr)
AU (1) AU2005285298A1 (fr)
CA (1) CA2578845A1 (fr)
WO (1) WO2006031420A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103286A2 (fr) * 2006-03-02 2007-09-13 Spherics, Inc. Formulations posologiques orales a liberation controlee
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP3620153A1 (fr) 2007-07-06 2020-03-11 Lupin Limited Compositions pharmaceutiques pour administration gastro-intestinale de médicaments
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP2013169146A (ja) * 2012-02-17 2013-09-02 Kabaya Shokuhin Kk 新規清涼菓子およびその製造方法
TWI439288B (zh) * 2012-10-05 2014-06-01 Univ China Medical 藥用載體及其製備方法與用途
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド ピロカルピンの医薬製剤
WO2015167434A1 (fr) * 2014-04-28 2015-11-05 Eduardo Fernandez Compositions pour la supplémentation nutritionnelle
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法
CN116159037B (zh) * 2023-04-25 2023-08-01 四川省川龙动科药业有限公司 一种防治仔猪结肠炎的靶向微丸组合物及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000112A1 (fr) * 1992-06-24 1994-01-06 Astra Aktiebolag Formulation orale destinee au traitement antibacterien gastrique, procede de preparation et d'utilisation de cette formulation
US6123965A (en) * 1996-01-26 2000-09-26 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6156348A (en) * 1996-06-25 2000-12-05 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
WO2002005820A1 (fr) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Dispersions solides de citrate de sildenafil ayant une forte solubilite dans l'eau
US6391294B1 (en) * 1997-08-21 2002-05-21 Reckitt Benckiser Healthcare (Uk) Limited In situ formation of polymeric material
US6391335B1 (en) * 1998-04-29 2002-05-21 Cima Labs Inc. Effervescent drug delivery system for oral administration
US20030113371A1 (en) * 2001-08-21 2003-06-19 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level by employing the hydrophilic matrix based oral controlled release antidiabetic composition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
WO1994000112A1 (fr) * 1992-06-24 1994-01-06 Astra Aktiebolag Formulation orale destinee au traitement antibacterien gastrique, procede de preparation et d'utilisation de cette formulation
US6123965A (en) * 1996-01-26 2000-09-26 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6156348A (en) * 1996-06-25 2000-12-05 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6391294B1 (en) * 1997-08-21 2002-05-21 Reckitt Benckiser Healthcare (Uk) Limited In situ formation of polymeric material
US6391335B1 (en) * 1998-04-29 2002-05-21 Cima Labs Inc. Effervescent drug delivery system for oral administration
WO2002005820A1 (fr) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Dispersions solides de citrate de sildenafil ayant une forte solubilite dans l'eau
US20030113371A1 (en) * 2001-08-21 2003-06-19 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level by employing the hydrophilic matrix based oral controlled release antidiabetic composition

Also Published As

Publication number Publication date
CA2578845A1 (fr) 2006-03-23
AU2005285298A1 (en) 2006-03-23
WO2006031420A2 (fr) 2006-03-23
EP1784167A2 (fr) 2007-05-16

Similar Documents

Publication Publication Date Title
JP2005511647A (ja) 経口用および口内用の成型粉薬錠剤を伴う圧縮環状錠剤
WO2007013975A3 (fr) Compositions et procedes destines a controler l'abus de medicaments
WO2007081948A3 (fr) Formulations de médicaments bioadhésifs pour administration par voie transmucosale orale
WO2006063189A3 (fr) Systeme d'administration de medicament a desintegration rapide
WO2006039499A3 (fr) Procede d'amelioration de la biodisponibilite d'agents therapeutiques administres par voie orale
IL181382A0 (en) Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
JP2009536147A5 (fr)
WO2007146805A3 (fr) Procédés destinés à l'administration de formes posologiques solides d'éthinyl estradiol et de ses promédicaments présentant une biodisponibilité améliorée
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
EP1807018A4 (fr) Systeme d'administration in situ de medicaments a liberation controlee
WO2007122635A3 (fr) Formulation à libération à libération contrôlée comprenant des médicaments anti-épilepiques
WO2008142572A3 (fr) Formulation de comprimé à libération contrôlée contenant de l'aluminométasilicate de magnésium
WO2003065982A3 (fr) Technique d'absorption de composes therapeutiques par l'intermediaire de transporteurs du colon
WO2007079082A3 (fr) Systeme gastrique a impulsions de liberation pour l'administration de medicaments
EP1957110A4 (fr) Procede pour la fabrication de formes pharmaceutiques a macher pour l'administration de medicament et produits associes
WO2006125819A3 (fr) Forme medicamenteuse orale, microparticulaire, anti-mesusage
EP2283843A3 (fr) Opioides pour le traitement de la bronchopneumopathie chronique obstructive (BPCO)
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
AU2004246837A1 (en) Orally-dispersible multilayer tablet
WO2006031420A3 (fr) Comprimes multicouche et formes posologiques bioadhesives
WO2007031887A3 (fr) Composition pharmaceutique de metformine a liberation lente et procede de production correspondant
EP2061448B1 (fr) Formulation à libération prolongée de naltréxone
WO2005112896A3 (fr) Forme posologique permettant l'administration de multiples formes medicamenteuses
IL187632A (en) 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
WO2007086079A3 (fr) Forme de dose a liberation soutenue de derives de phenothiazine contenant un canalisateur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007530225

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2578845

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005285298

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005792519

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005285298

Country of ref document: AU

Date of ref document: 20050829

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005285298

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005792519

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11661541

Country of ref document: US